Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Advanced Gastric Adenocarcinoma”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Early research (Phase 1)Enrolling By InvitationNCT07218003
What this trial is testing

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Who this might be right for
Non Small Cell Lung CancerCervical CancerHead and Neck Squamous Cell Cancer+7 more
Rondo Therapeutics 149
Testing effectiveness (Phase 2)UnknownNCT02839954
What this trial is testing

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

Who this might be right for
Hepatocellular CarcinomaNon-small Cell Lung CancerPancreatic Carcinoma+4 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Not applicableEnded earlyNCT00904514
What this trial is testing

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 241
Not applicableUnknownNCT05053295
What this trial is testing

Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric Cancer

Who this might be right for
Relapsed or Advanced Gastric AdenocarcinomaGastro-esophageal Junction Cancer
Gangnam Severance Hospital 20
Early research (Phase 1)Ended earlyNCT04594811
What this trial is testing

NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma

Who this might be right for
Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)
NeoImmuneTech 10
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Early research (Phase 1)Study completedNCT00004065
What this trial is testing

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

Who this might be right for
Bladder CancerBreast CancerColorectal Cancer+9 more
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Study completedNCT01262482
What this trial is testing

Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment

Who this might be right for
Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment)
Grupo Espanol Multidisciplinario del Cancer Digestivo 41
Early research (Phase 1)Study completedNCT04430842
What this trial is testing

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Who this might be right for
AstrocytomaBrain CancerBrain Metastases+20 more
Quadriga Biosciences, Inc. 15
Early research (Phase 1)Study completedNCT00161187
What this trial is testing

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Who this might be right for
Cancer
University of Medicine and Dentistry of New Jersey 37
Early research (Phase 1)Looking for participantsNCT06999187
What this trial is testing

DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Who this might be right for
Triple Negative Breast CancerHER2-negative Breast CancerNon Small Cell Lung Cancer+9 more
Dren Bio 96